TIMP3 and diabetes mellitus: Results indicated that MacT3 mice after 12 weeks from the induction of diabetes by a low-dose STZ protocol treatment, showed a reduction in renal lesions, albuminuria, inflammation and fibrosis and prevention of the loss of podocytes [16], suggesting that TIMP3 may halt or slow the progression of diabetic kidney complications, thus representing a valid approach to characterize the pathogenesis of DN and to develop new avenues to diagnose and treat this disorder.